Remestemcel-L reduces ARDS mortality in those under 65 years old
SHARES
New data shows patients with COVID-19-related Acute Respiratory Distress Syndrome (ARDS) were up to 75 percent less likely to die when treated with remestemcel-L and dexamethasone.
Mesoblast Limited has announced the 60-day results from the randomised controlled trial evaluating remestemcel-L in 222 ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS). This trial was ended early after the third interim analysis.
The data shows remestemcel-L reduced mortality through day 60 by 46 percent in the pre-specified group (below age 65 years), but not in patients 65 years or older. Additionally, remestemcel-L reduced mortality by 75 percent and increased days alive off mechanical ventilation in patients under age 65 when combined with dexamethasone, in comparison with controls on dexamethasone.
Management Team Mesoblast has a highly experienced management team made up of individuals who have held senior positions in international pharmaceutical and. | February 16, 2021
Mesoblast shares smashed on Revascor trial results
Share
Shares in Mesoblast tumbled more than 15 per cent on Tuesday after the regenerative medicine company missed the primary goal in a trial of its heart failure treatmentRevascor.
Mesoblast said its 537-patient phase three trial of Revascor mesenchymal precursor cells, used to treat chronic heart failure, had not met its primary end point, but had reduced cardiac deaths.
Mesoblast derives stem cells from bone marrow, and uses mesenchymal adult stem cells to assist the body’s repair and regenerative process.
The Melbourne-based biotech stock fell 69¢, or 15.2 per cent, to $3.85 on Tuesday.
Mesoblast s stem cells are derived from bone marrow. It uses mesenchymal adult stem cells to assist the body s repair and regenerative process following disease or injury by releasing proteins and other cell-signalling molecules, which reduce inflammation and begin the job of regeneration.